CA13650/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1986	1
1995	2
1996	2
1997	1
1998	5
1999	2
2000	2
2001	6
2002	4
2003	9
2004	13
2005	7
2006	9
2007	4
2008	2
2009	9
2010	8
2011	8
2012	4
2013	10
2014	7
2015	6
2016	1
2017	1
2024	0

1

Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.

Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M; Eastern Cooperative Oncology Group. Belani CP, et al. J Clin Oncol. 2005 Jun 1;23(16):3760-7. doi: 10.1200/JCO.2005.09.108. Epub 2005 Apr 18. J Clin Oncol. 2005. PMID: 15837967 Review.

2

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. Dhodapkar MV, et al. Blood. 2001 Jul 1;98(1):41-8. doi: 10.1182/blood.v98.1.41. Blood. 2001. PMID: 11418461 Free article. Clinical Trial.

3

Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.

Kovacs MJ, Davies GA, Chapman JA, Bahlis N, Voralia M, Roy J, Kouroukis CT, Chen C, Belch A, Reece D, Zhu L, Meyer RM, Shepherd L, Stewart KA. Kovacs MJ, et al. Br J Haematol. 2015 Feb;168(4):511-7. doi: 10.1111/bjh.13176. Epub 2014 Oct 10. Br J Haematol. 2015. PMID: 25302852 Free article. Clinical Trial.

4

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale.

Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC. Eton DT, et al. J Clin Epidemiol. 2004 Sep;57(9):898-910. doi: 10.1016/j.jclinepi.2004.01.012. J Clin Epidemiol. 2004. PMID: 15504633

5

Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.

Witte RS, Cnaan A, Mansour EG, Barylak E, Harris JE, Schutt AJ. Witte RS, et al. Cancer. 2001 Mar 1;91(5):1020-8. Cancer. 2001. PMID: 11251955 Clinical Trial.

6

Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.

Gordon LI, Anderson J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P. Gordon LI, et al. J Clin Oncol. 1996 Apr;14(4):1275-81. doi: 10.1200/JCO.1996.14.4.1275. J Clin Oncol. 1996. PMID: 8648384 Clinical Trial.

7

Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study.

Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Hoffman JP, et al. J Clin Oncol. 1998 Jan;16(1):317-23. doi: 10.1200/JCO.1998.16.1.317. J Clin Oncol. 1998. PMID: 9440759 Clinical Trial.

8

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.

Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA, Hahn RG, Dutcher JP, Wiernik PH, Oken MM; Eastern Cooperative Oncology Group. Radin AI, et al. Cancer. 2003 Jul 1;98(1):100-9. doi: 10.1002/cncr.11486. Cancer. 2003. PMID: 12833462 Free article. Clinical Trial.

9

Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial.

Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ Sr. Witte RS, et al. Invest New Drugs. 1998;16(2):191-5. doi: 10.1023/a:1006159525793. Invest New Drugs. 1998. PMID: 9848585 Clinical Trial.

10

A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.

Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM Jr, Benson AB 3rd. Marsh Rde W, et al. Am J Clin Oncol. 2007 Feb;30(1):26-31. doi: 10.1097/01.coc.0000251235.46149.43. Am J Clin Oncol. 2007. PMID: 17278891 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

110 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year